knowledge -WSS

knowledge

author：focus 2025-09-27 09:53:51 - browse：63

Judge's gavel — Legal experts unpacked the pharmaceutical industry's scattershot approach to challenging Medicare's new power to negotiate drug prices. Adobe

WASHINGTON — The pharmaceutical industry has been filing a lawsuit here, there, and pretty much everywhere.

Drugmakers lost a two-decade long lobbying fight in Congress last summer when Democrats gave Medicare more power to choose what it pays for prescription drugs. Now, they’re taking their battle to the courts.

Merck filed suit in the District of Columbia. Bristol Myers Squibb filed in New Jersey. The Chamber of Commerce filed in Ohio. PhRMA filed in Texas. And there’s no reason to believe the barrage of lawsuits will stop anytime soon.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Immune cells and nerve overgrowth may explain recurring UTI pain

WSS

Was Amgen transparent enough on FDA's concern on cancer drug?

Medicare drug price negotiation hearing pits pharma v Biden admin

The public health thinking behind the CDC’s new Covid guidance

Harvard's David Sinclair gets blowback over aging

Ancient Greek ideas underpin modern concepts of pregnancy

FDA panel signals lack of confidence in Amgen cancer drug data

explore

knowledge

focus

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Why Charlie Gard's case is so disturbing to Americans

Duchenne breakthrough therapy leaves behind pioneering families

What to expect at HLTH 2023, the health care industry conference

Novavax promises a turnaround & Lilly roils the obesity market

Families look for replacement for GSK asthma drug Flovent

Tori Bowie and the unacceptable rates of Black maternal death

Stem cell biologist probes earliest stages of human development

The cancer drug shortage isn’t new — and neither are the solutions

Medicare drug price negotiation continues, as pharma counteroffers

hotspot

Was Amgen transparent enough on FDA's concern on cancer drug?

Why Talkspace is targeting Medicare, a tricky market

Biden's 'march

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

The untold story of TV’s first prescription drug ad

Medicare drug price negotiation continues, as pharma counteroffers

hotspot

Wikipedia

knowledge

hotspot